With encouraging small-animal data in hand, Vical Inc. said it will begin human testing of its anthrax DNA vaccine by the end of this year. (BioWorld Today)
Talk about a hard call.Investors may have been quick to attach their unmistakable meaning to last month's disclosure by VaxGen Inc. of disappointing Phase III results for its HIV vaccine - the company's stock value nosedived by 47.3 percent - but the scientific world was far from convinced a disaster had taken place.
Science is all about experiments, so here's an idea for the blackboard: Imagine a world where biotechnology pays pharmaceutical companies to develop compounds.
NEW YORK - FDA Commissioner Mark McClellan's face projected on a huge screen in the American city hit hard by terrorists on 9/11 gave him the appearance of a commander exhorting his troops, as he offered details regarding Project Bioshield. (BioWorld Today)
